Prognostic Value of an Activation State Marker for Epidermal Growth Factor Receptor in Tissue Microarrays of Head and Neck Cancer
- 1 March 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (5) , 2834-2843
- https://doi.org/10.1158/0008-5472.can-05-2994
Abstract
Overexpression and mutation of epidermal growth factor receptors (EGFR) have been shown to be important in the prognosis of several cancers, including head and neck cancers. However, our inability to define the activation status of these and other receptors limits our ability to assess the importance of these pathways and to exploit effectively new molecularly targeted treatments directed at their catalytic activities. Here we describe the use of automated, high-throughput fluorescence lifetime imaging microscopy to measure EGFR autophosphorylation status by fluorescence resonance energy transfer (FRET) in head and neck tumors. We have correlated FRET efficiency with the clinical and survival data. The results from head and neck arrays show that high FRET efficiency is correlated with worsening disease-free survival but not with overall survival. This powerful tool could be exploited as a new independent quantitative prognostic factor in clinical decisions and cancer management. (Cancer Res 2006; 66(5): 2834-43)Keywords
This publication has 33 references indexed in Scilit:
- Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2005
- Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods?European Journal Of Cancer, 2005
- Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patientsThe Journal of Pathology, 2004
- Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor TissuesJournal of Histochemistry & Cytochemistry, 2004
- Expression of EGFR and Cerb-B2 as prognostic factors in cancer of the tongueOral Oncology, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?The Oncologist, 2002
- TGF-α antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivoGene Therapy, 2000
- Imaging Protein Kinase Cα Activation in CellsScience, 1999
- Prognostic Value of EGFR and TGF-α in Early Laryngeal Cancer Treated With RadiotherapyThe Laryngoscope, 1996